Distributions of Kozak, variable number of tandem repeats, and human platelet antigen–2 mutations in cases and controls
| Platelet GP Ibα genotype . | Controls (n = 205) . | Patients (n = 219) . | Unadjusted OR . | 95% CI . | P . |
|---|---|---|---|---|---|
| Kozak | |||||
| TT | 14 (75.6%) | 135 (65.8%) | 1 (reference) | — | — |
| TC | 44 (22.8%) | 66 (32.2%) | 1.62 | 1.03-2.54 | .03* |
| CC | 3 (1.6%) | 4 (2.0%) | 1.44 | 0.32-6.56 | .64 |
| VNTR | |||||
| DD | 4 (4.1%) | 5 (4.3%) | 1 (reference) | — | — |
| DC | 17 (8.8%) | 26 (12.6%) | 1.36 | 0.44-4.22 | .59 |
| CC | 162 (83.9%) | 164 (79.2%) | 0.90 | 0.34-2.39 | .83 |
| BC | 8 (2.1%) | 9 (2.4%) | 1.11 | 0.22-5.63 | .90 |
| BB | 2 (1.0%) | 3 (1.4%) | 1.33 | 0.18-10.12 | .78 |
| HPA-2 | |||||
| a+b− | 169 (88.5%) | 175 (85.0%) | 1 (reference) | — | — |
| a+b+ | 19 (9.9%) | 31 (15.0%) | 1.58 | 0.85-2.8 | .14 |
| a−b+ | 3 (1.6%) | 0 | — | — | — |
| Platelet GP Ibα genotype . | Controls (n = 205) . | Patients (n = 219) . | Unadjusted OR . | 95% CI . | P . |
|---|---|---|---|---|---|
| Kozak | |||||
| TT | 14 (75.6%) | 135 (65.8%) | 1 (reference) | — | — |
| TC | 44 (22.8%) | 66 (32.2%) | 1.62 | 1.03-2.54 | .03* |
| CC | 3 (1.6%) | 4 (2.0%) | 1.44 | 0.32-6.56 | .64 |
| VNTR | |||||
| DD | 4 (4.1%) | 5 (4.3%) | 1 (reference) | — | — |
| DC | 17 (8.8%) | 26 (12.6%) | 1.36 | 0.44-4.22 | .59 |
| CC | 162 (83.9%) | 164 (79.2%) | 0.90 | 0.34-2.39 | .83 |
| BC | 8 (2.1%) | 9 (2.4%) | 1.11 | 0.22-5.63 | .90 |
| BB | 2 (1.0%) | 3 (1.4%) | 1.33 | 0.18-10.12 | .78 |
| HPA-2 | |||||
| a+b− | 169 (88.5%) | 175 (85.0%) | 1 (reference) | — | — |
| a+b+ | 19 (9.9%) | 31 (15.0%) | 1.58 | 0.85-2.8 | .14 |
| a−b+ | 3 (1.6%) | 0 | — | — | — |
Results are presented as frequencies (%) with unadjusted odd ratio (OR) and 95% confidence intervals (CI). GP indicates glycoprotein; VNTR, variable number of tandem repeats; HPA, human platelet antigen.
Significant.